EQS-News: Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard
EQS-News: M1 Kliniken AG
/ Key word(s): Investment
Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard
05.02.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
The two members of the Management Board of M1 Kliniken AG, Mr Attila Strauss and Mr Kilian Brenske, acquired a total of 1.5 million shares in the company from MPH Health Care AG on 2 February 2024. The Co-CEOs justify the share purchase with their confidence in the long-term growth prospects of M1 Kliniken AG and the desire to participate even more strongly in the strategic direction and development of the company.
Co-CEO Kilian Brenske explains: "We are firmly convinced that our investment will further strengthen investor confidence. The profitable growth of our group of companies remains the focus of our actions." Co-CEO, Attila Strauss, adds: "Intensifying communication with external investors, a shareholder-friendly dividend policy and also a possible uplisting to the Prime Standard will be further focal points." About M1 Kliniken AG: M1 Kliniken AG is the leading fully integrated provider of aesthetic medical health services in Europe. In the aesthetic and surgical fields, the group offers products and services with the highest quality standards. Currently, under the brand "M1 Med Beauty," beauty medical treatments are offered at 59 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating rooms and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving internationalisation and is currently present in ten countries.
Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: [email protected]
05.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
M1 Kliniken AG |
|
Grünauer Straße 5 |
|
12557 Berlin |
|
Germany |
Phone: |
+49 (0)30 347 47 44 14 |
Fax: |
+49 (0)30 347 47 44 17 |
E-mail: |
[email protected] |
Internet: |
https://www.m1-kliniken.de |
ISIN: |
DE000A0STSQ8 |
WKN: |
A0STSQ |
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1830421 |
|
End of News |
EQS News Service |
1830421 05.02.2024 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
47,19 |
65,21 |
77,27 |
159,59 |
314,61 |
285,29 |
316,32 |
EBITDA1,2 |
6,18 |
7,17 |
11,33 |
8,89 |
17,82 |
15,41 |
21,01 |
EBITDA-Marge3 |
13,10 |
11,00 |
14,66 |
5,57 |
5,66 |
5,40 |
|
EBIT1,4 |
5,71 |
6,46 |
7,93 |
4,41 |
12,13 |
9,35 |
15,70 |
EBIT-Marge5 |
12,10 |
9,91 |
10,26 |
2,76 |
3,86 |
3,28 |
4,96 |
Jahresüberschuss1 |
5,78 |
6,61 |
9,73 |
7,43 |
10,88 |
7,07 |
11,67 |
Netto-Marge6 |
12,25 |
10,14 |
12,59 |
4,66 |
3,46 |
2,48 |
3,69 |
Cashflow1,7 |
2,09 |
2,86 |
-5,37 |
9,54 |
15,68 |
20,77 |
7,81 |
Ergebnis je Aktie8 |
0,38 |
0,39 |
0,56 |
0,37 |
0,45 |
0,22 |
0,54 |
Dividende8 |
0,30 |
0,30 |
0,00 |
0,00 |
0,00 |
0,00 |
0,30 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: wetreu NTRG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
M1 Kliniken |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0STSQ |
18,400 |
Kaufen |
361,44 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
19,78 |
27,03 |
0,73 |
42,79 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,49 |
46,28 |
1,14 |
16,65 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,00 |
0,50 |
2,72 |
17.07.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
06.06.2024 |
03.09.2024 |
19.11.2024 |
23.05.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
6,33% |
46,15% |
64,29% |
130,58% |
|
|